Rhumbline Advisers Aldeyra Therapeutics, Inc. Transaction History

Rhumbline Advisers

$105 Billion
Q2 2024

A detailed history of Rhumbline Advisers transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 76,981 shares of ALDX stock, worth $411,078. This represents 0.0% of its overall portfolio holdings.

Number of Shares

76,981

Previous 64,074 20.14%

Holding current value

$411,078

Previous $209,000 21.53%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	BUY	$3.25 - $4.72 $41,947 - $60,921	12,907 Added 20.14%	76,981 $254,000
Q1 2024 May 09, 2024	BUY	$2.77 - $4.22 $6,124 - $9,330	2,211 Added 3.57%	64,074 $209,000
Q4 2023 Feb 08, 2024	SELL	$1.47 - $6.06 $954 - $3,932	-649 Reduced 1.04%	61,863 $217,000
Q3 2023 Nov 09, 2023	BUY	$6.11 - $8.16 $18,439 - $24,626	3,018 Added 5.07%	62,512 $417,000
Q2 2023 Aug 08, 2023	BUY	$7.11 - $11.89 $423,002 - $707,383	59,494 New	59,494 $499,000
Q2 2022 Aug 11, 2022	SELL	$2.43 - $4.85 $115,658 - $230,840	-47,596 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$3.25 - $5.17 $16,237 - $25,829	4,996 Added 11.73%	47,596 $212,000
Q4 2021 Feb 10, 2022	SELL	$3.5 - $9.63 $2,985 - $8,214	-853 Reduced 1.96%	42,600 $170,000
Q3 2021 Nov 12, 2021	BUY	$7.94 - $11.31 $15,268 - $21,749	1,923 Added 4.63%	43,453 $382,000
Q2 2021 Aug 05, 2021	BUY	$10.44 - $14.85 $433,573 - $616,720	41,530 New	41,530 $471,000
Q2 2020 Aug 13, 2020	SELL	$1.97 - $5.05 $60,644 - $155,459	-30,784 Closed	0 $0
Q4 2019 Feb 05, 2020	BUY	$4.73 - $7.98 $676 - $1,141	143 Added 0.47%	30,784 $179,000
Q3 2019 Oct 23, 2019	BUY	$4.41 - $6.12 $3,113 - $4,320	706 Added 2.36%	30,641 $161,000
Q2 2019 Aug 14, 2019	BUY	$6.0 - $9.0 $16,512 - $24,768	2,752 Added 10.12%	29,935 $180,000
Q1 2019 May 01, 2019	BUY	$7.14 - $9.85 $28,631 - $39,498	4,010 Added 17.3%	27,183 $245,000
Q4 2018 Jan 31, 2019	BUY	$7.26 - $13.29 $67,227 - $123,065	9,260 Added 66.56%	23,173 $192,000
Q3 2018 Nov 07, 2018	SELL	$6.8 - $14.35 $2,332 - $4,922	-343 Reduced 2.41%	13,913 $192,000
Q2 2018 Aug 06, 2018	BUY	$6.95 - $9.18 $99,079 - $130,870	14,256 New	14,256 $113,000

Others Institutions Holding ALDX

# of Institutions

107

Shares Held

35.2M

Call Options Held

153K

Put Options Held

83.9K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $311M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Aldeyra Therapeutics, Inc. Transaction History